Karuna Therapeutics, Inc. (KRTX)

NASDAQ: KRTX · Delayed Price · USD
100.44
-7.48 (-6.93%)
At close: May 18, 2022 4:00 PM
107.92
7.48 (7.45%)
After-hours:May 18, 2022 4:53 PM EDT
Market Cap3.00B
Revenue (ttm)36.96M
Net Income (ttm)-171.53M
Shares Out29.88M
EPS (ttm)-4.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume254,413
Open104.23
Previous Close107.92
Day's Range99.20 - 104.50
52-Week Range92.26 - 161.98
Beta1.95
AnalystsBuy
Price Target181.31 (+80.5%)
Earnings DateMay 5, 2022

About KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psych...

IndustryBiotechnology
IPO DateJun 28, 2019
Employees118
Stock ExchangeNASDAQ
Ticker SymbolKRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for KRTX stock is "Buy." The 12-month stock price forecast is 181.31, which is an increase of 80.52% from the latest price.

Price Target
$181.31
(80.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and...

1 day ago - Business Wire

Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss

Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

1 week ago - Zacks Investment Research

Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

2 weeks ago - Business Wire

Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

2 weeks ago - Business Wire

Karuna Therapeutics to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

2 months ago - Business Wire

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia.  T...

2 months ago - Benzinga

Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

2 months ago - Business Wire

Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster

Let's take a deeper dive into Karuna Therapeutics Inc. ( KRTX , Financial), which was one of the potential takeover targets I discussed last week.

2 months ago - GuruFocus

Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

3 months ago - Business Wire

3 Can't-Miss Biotech Events Coming Up in 2022

This could be a very exciting year for these drugmakers.

Other symbols:ALNYICPT
4 months ago - The Motley Fool

12 Super Small-Cap Stocks to Buy for 2022 and Beyond

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

4 months ago - Kiplinger

Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

4 months ago - Business Wire

Karuna Therapeutics CEO discusses the biotech firm's drug trials for schizophrenia

Karuna Therapeutics CEO Dr. Steve Paul appeared on Wednesday's episode of "Mad Money."

5 months ago - CNBC Television

Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

5 months ago - Business Wire

Why Karuna Therapeutics Stock Tumbled This Week

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

6 months ago - The Motley Fool

Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercializatio...

BOSTON & SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines f...

Other symbols:ZLAB
6 months ago - Business Wire

Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

6 months ago - Business Wire

Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

8 months ago - Business Wire

Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

8 months ago - Business Wire

11 Small-Cap Stocks the Analysts Love for the Rest of 2021

A recent pullback has created buying opportunities for many small-cap stocks. Here are the ones the pros are most bullish on.

9 months ago - Kiplinger

Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

9 months ago - Business Wire

Karuna Therapeutics to Present at 2021 Wedbush PacGrow Healthcare Virtual Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

9 months ago - Business Wire

Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy ...

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

10 months ago - Business Wire

Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...

1 year ago - Business Wire

PureTech Founded Entity Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced the pricing of an underwritten public offering.

1 year ago - Business Wire